Connext Administers First CNT201 Dose for Dupuytren's Contracture

Connext has recently announced a significant breakthrough with the initial administration of CNT201, an innovative therapeutic treatment for Dupuytren's contracture, marking the beginning of its clinical trials in Australia. This condition, characterized by the thickening of the fascia in the palm due to excessive collagen, leads to permanently bent fingers, severely impacting patients' daily lives. Currently, there is no definitive cure, with existing treatments primarily involving surgery or localized collagenase injections, which have yielded satisfactory results among patients.

The U.S. FDA has granted Investigational New Drug (IND) approval for the Phase 1/2 clinical trials of CNT201, and the trial has also successfully completed the Clinical Trial Notification (CTN) process in Australia. The Phase 1 trial is underway in Australia, being carried out across three hospitals. This segment of the trial involves administering single doses at four escalating levels to patients with Dupuytren's contracture. Following each administration, a four-week evaluation period is conducted to assess the safety, tolerability, efficacy, pharmacokinetics, and immunogenicity of the treatment.

Connext is aiming to gather proof-of-concept (PoC) data by mid-next year, which will help in identifying the optimal dose for Phase 2 of the trial. The second phase of the trial is planned to begin in the latter part of the year, based on the findings from the initial phase.

CEO Woojong Lee expressed his enthusiasm about this development, noting the milestone represents a significant step forward in providing new hope for those affected by Dupuytren's contracture. Lee emphasized the company's dedication to developing a safer and more effective treatment that could substantially improve the quality of life for these patients.

Connext has been making strides not only with CNT201 but also on a broader scale. The company successfully secured a Series B investment at the end of last year and was chosen for the Scale-Up TIPS program. This financial support has been instrumental in enabling Connext to initiate and advance global clinical trials for Dupuytren's contracture. Additionally, Connext is working on extending the application of its innovative treatments to other conditions, including Peyronie's disease and cellulite.

This promising start to the clinical trials of CNT201 in Australia is a testament to Connext's commitment to medical innovation and patient care. The ongoing research and trials are crucial in paving the way for new, effective treatments for chronic conditions that currently lack comprehensive solutions, potentially transforming the landscape of therapeutic interventions for such diseases.

How to obtain the latest research advancements in the field of biopharmaceuticals?

In the Synapse database, you can keep abreast of the latest research and development advances in drugs, targets, indications, organizations, etc., anywhere and anytime, on a daily or weekly basis. Click on the image below to embark on a brand new journey of drug discovery!